Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 May 28

PMID 35626354

Authors

Ji-Hee Haam

Yun Kyong Lee

Eunkyung Suh

Young-Sang Kim

Affiliations

Soon will be listed here.

Abstract

The liver is an essential organ that manufactures energy through various metabolic pathways; thus, exploring the intermediate metabolites in nonalcoholic fatty liver disease (NAFLD) may help discover novel parameters in hepatic steatosis or fibrosis. The present study aimed to investigate the traits of urine organic acid metabolites in participants with hepatic steatosis and fibrosis in nonalcoholic Korean adults. Hepatic steatosis and fibrosis, in 68 men and 65 women, were evaluated using quantification by proton density fat fraction with magnetic resonance (MR) imaging and MR elastography, respectively. Urine metabolites were obtained using a high-performance liquid chromatography-mass spectrometry analysis. The candidate metabolites were included in the logistic regression models for hepatic steatosis and fibrosis. The association between high p-hydroxyphenyllactate levels and hepatic steatosis was not independent of body mass index and Homeostatic Model Assessment-insulin resistance. High ethylmalonate, β-hydroxybutyrate, and sulfate levels were significantly related to a low probability of hepatic fibrosis, independent of covariates. In conclusion, urine metabolites were not related to hepatic steatosis independent of obesity and insulin resistance, while several metabolites were specifically associated with hepatic fibrosis. Further study is required to verify the diagnostic value of the metabolites in a population with wide-spectrum NAFLD.

Citing Articles

Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.

Yuan H, Jung E, Chae S, Jung S, Daily J, Park S Nutrients. 2024; 16(18).

PMID: 39339660 PMC: 11434757. DOI: 10.3390/nu16183061.

References

Lichtinghagen R, Pietsch D, Bantel H, Manns M, Brand K, Bahr M . The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013; 59(2):236-42. DOI: 10.1016/j.jhep.2013.03.016. View

Caussy C, Hsu C, Lo M, Liu A, Bettencourt R, Ajmera V . Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018; 68(3):918-932. PMC: 6151296. DOI: 10.1002/hep.29892. View

Hagstrom H, Elfwen O, Hultcrantz R, Stal P . Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2018; 2018:1942648. PMC: 6051106. DOI: 10.1155/2018/1942648. View

Paparo F, Cenderello G, Revelli M, Bacigalupo L, Rutigliani M, Zefiro D . Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. Biomed Res Int. 2015; 2015:758164. PMC: 4383409. DOI: 10.1155/2015/758164. View

Qi S, Xu D, Li Q, Xie N, Xia J, Huo Q . Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clin Chim Acta. 2017; 473:89-95. DOI: 10.1016/j.cca.2017.08.022. View

Guha I, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S . Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2007; 47(2):455-60. DOI: 10.1002/hep.21984. View

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

An Y, Chen S, Deng Y, Wang Z, Funcke J, Shah M . The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol. 2021; 75(2):387-399. PMC: 8292187. DOI: 10.1016/j.jhep.2021.03.006. View

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

10.

Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R . Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int. 2015; 10(4):632-9. DOI: 10.1007/s12072-015-9679-0. View

11.

Gallagher R, Pollard L, Scott A, Huguenin S, Goodman S, Sun Q . Laboratory analysis of organic acids, 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018; 20(7):683-691. DOI: 10.1038/gim.2018.45. View

12.

Chen J, Yin M, Talwalkar J, Oudry J, Glaser K, Smyrk T . Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology. 2016; 283(2):418-428. PMC: 5395333. DOI: 10.1148/radiol.2016160685. View

13.

Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z . Metabolic Changes of Hepatocytes in NAFLD. Front Physiol. 2021; 12:710420. PMC: 8437340. DOI: 10.3389/fphys.2021.710420. View

14.

Kim H . Recent advances in nonalcoholic fatty liver disease metabolomics. Clin Mol Hepatol. 2021; 27(4):553-559. PMC: 8524071. DOI: 10.3350/cmh.2021.0127. View

15.

Muting D, Wuzel H, Bucsis L, Flasshoff H . Urinary p-hydroxyphenyllactic acid as indicator of hepatic encephalopathy in patients with hepatic cirrhosis. Lancet. 1985; 2(8468):1365-6. DOI: 10.1016/s0140-6736(85)92662-5. View

16.

Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

17.

Linster C, Noel G, Stroobant V, Vertommen D, Vincent M, Bommer G . Ethylmalonyl-CoA decarboxylase, a new enzyme involved in metabolite proofreading. J Biol Chem. 2011; 286(50):42992-3003. PMC: 3234807. DOI: 10.1074/jbc.M111.281527. View

18.

Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J . Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2014; 274(2):416-25. PMC: 4314291. DOI: 10.1148/radiol.14140754. View

19.

Scolamiero E, Cozzolino C, Albano L, Ansalone A, Caterino M, Corbo G . Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. Mol Biosyst. 2015; 11(6):1525-35. DOI: 10.1039/c4mb00729h. View

20.

Yin M, Chen J, Glaser K, Talwalkar J, Ehman R . Abdominal magnetic resonance elastography. Top Magn Reson Imaging. 2009; 20(2):79-87. PMC: 3068842. DOI: 10.1097/RMR.0b013e3181c4737e. View